AstraZeneca Pharma India gets CDSCO Panel nod for Anti-cancer Drug Osimertinib Tablets 40 mg and 80 mg Dr. Divya Colin20 May 2025 6:00 PM ISTNew Delhi: With the condition of conducting a Phase IV clinical trial study, the Subject Expert Committee (SEC) functional under the Central Drug...
AstraZeneca successfully completes acquisition of EsoBiotec Ruchika Sharma20 May 2025 12:27 PM ISTAstraZeneca has successfully completed the acquisition of EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated...
AstraZeneca Trixeo Aerosphere approved in UK as inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential Ruchika Sharma13 May 2025 10:30 AM ISTCambridge: AstraZeneca's Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF), already licensed for the treatment of...
AstraZeneca Calquence plus chemoimmunotherapy approved in EU for 1st-line mantle cell lymphoma Ruchika Sharma7 May 2025 12:30 PM ISTCambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the...
Medical Bulletin 05/ May/ 2025 Dr. Garima Soni5 May 2025 3:00 PM ISTHere are the top medical news for the day:Too Much Chicken? New Research Finds Link to Increased Risk of Early DeathA recent study published in the...
AI-Enabled X-Rays Help Detect Lung Cancer Risk in 50,000 Patients Worldwide: Study Shows Dr. Garima Soni5 May 2025 8:30 AM ISTAstraZeneca, in partnership with health-tech company Qure.ai, has successfully completed over 5 million artificial intelligence (AI)-enabled chest...
AstraZeneca Breztri met primary endpoints in Phase III trials in asthma Ruchika Sharma4 May 2025 10:30 AM ISTAstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that...
Fixed duration Calquence based regimens recommended for EMA Committee for chronic lymphocytic leukaemia: AstraZenaca Ruchika Sharma30 April 2025 1:30 PM ISTAstraZeneca has announced that a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without...
AstraZeneca discontinues Phase 3 trial of Truqap in metastatic castration-resistant prostate cancer Ruchika Sharma30 April 2025 12:14 PM ISTTruqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics.
AstraZeneca rejoins leading US drug lobby group Ruchika Sharma23 April 2025 9:30 AM ISTAstraZeneca has rejoined the Pharmaceutical Research and Manufacturers of America (PhRMA), the main U.S. drug lobby group, nearly two years...
AstraZeneca Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer Ruchika Sharma4 April 2025 3:30 PM ISTCambridge: AstraZeneca has announced that the Company's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union...
AstraZeneca gets USFDA approval for perioperative Imfinzi for bladder cancer Ruchika Sharma1 April 2025 2:15 PM ISTImfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
